The Texas-based biotech raised just $9 million in an unorthodox IPO earlier this year, but FDA move should slice months off the time it takes to complete phase 2 trials.

Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.

Cyclacel Pharmaceuticals (CYCC) stock is soaring on Monday afternoon as Tang Capital revealed a passive stake in the company.

H.C. Wainwright analysts are bullish on Cyclacel Pharmaceuticals (CYCC) ahead of the company's acute myeloid leukemia study results.

These stocks are ready to break out and trade higher from current levels.

These under-$10 stocks are within range of triggering breakout trades.

These under-$10 stocks are setting up to break out and trade higher from current levels.

Last year was better for some billionaires than it was others. Bill Ackman’s theme song? 'All I Do Is Win.' Carl Icahn’s? 'Maybe Next Year.' Six stocks that really hurt.

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Surging U.S. output, set against fading demand from China, as global oil prices on the back foot again Monday and adding further downward pressure to domestic gas prices.

“Oyu Tolgoi is an attractive tier one asset, and we remain highly focused on and optimistic about its transformation into one of the world’s great copper mines," Turquoise Hill said.

The National Highway Transit Safety Administration received over 50 complaints over brake hose ruptures.